Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on February 27, 2019. The filing serves to incorporate a news release by reference into the company's Registration Statement on Form F-10 (File No. 333-222413). The registrant is a foreign private issuer reporting pursuant to Rule 13A-16 or 15D-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a cover sheet and exhibit index rather than a financial statement.
Material Changes
The primary material event disclosed in this filing is the closing of an At-The-Market (ATM) facility, as detailed in the incorporated news release (Exhibit 99.1). No comparative financial changes are provided in the text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. The document focuses solely on the administrative incorporation of the ATM facility news release.
Investor Verification Checklist
- Verify the specific terms and capacity of the At-The-Market facility referenced in Exhibit 99.1.
- Review the full text of the news release incorporated by reference for details on the ATM program.
- Consult the Registration Statement on Form F-10 (File No. 333-222413) for broader context on the offering.
- Note that this filing does not contain audited or unaudited financial statements for the period.